Purpose: Recent studies have identified genetic variants associated with increased serum prostate specific antigen concentrations and prostate cancer risk, raising the possibility of diagnostic bias. By correcting for the effects of these variants on prostate specific antigen, it may be possible to create a personalized prostate specific antigen cutoff to more accurately identify individuals for whom biopsy is recommended. Therefore, we determined how many men would continue to meet common biopsy criteria after genetic correction of their measured prostate specific antigen concentrations.
Materials And Methods: The genotypes of 4 single nucleotide polymorphisms previously associated with serum prostate specific antigen levels (rs2736098, rs10788160, rs11067228 and rs17632542) were determined in 964 healthy Caucasian volunteers without prostate cancer. Genetic correction of prostate specific antigen was performed by dividing an individual's prostate specific antigen value by his combined genetic risk. Analyses were used to compare the percentage of men who would meet commonly used biopsy thresholds (2.5 ng/ml or greater, or 4.0 ng/ml or greater) before and after genetic correction.
Results: Genetic correction of serum prostate specific antigen results was associated with a significantly decreased percentage of men meeting biopsy thresholds. Genetic correction could lead to a 15% or 20% relative reduction in the total number of biopsies using a biopsy threshold of 2.5 ng/ml or greater, or 4.0 ng/ml or greater, respectively. In addition, genetic correction could result in an 18% to 22% reduction in the number of potentially unnecessary biopsies and a 3% decrease in potentially delayed diagnoses.
Conclusions: Our results suggest that 4 single nucleotide polymorphisms can be used to adjust a man's measured prostate specific antigen concentration and potentially delay or prevent unnecessary prostate biopsies in Caucasian men.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301 | PMC |
| http://dx.doi.org/10.1016/j.juro.2012.12.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Promising Biological Role of Postbiotics in Treating Human Infertility.
Probiotics Antimicrob Proteins
January 2025
Department of Food Science and Technology, Faculty of Nutrition & Food Sciences, Nutrition, Tabriz, Iran.
Infertility poses a global challenge that impacts a significant proportion of the populace. Presently, there is a substantial emphasis on investigating the potential of probiotics and their derivatives, called postbiotics, as an alternative therapeutic strategy for addressing infertility. The term of "postbiotics" refers to compounds including peptides, enzymes, teichoic acids, and muropeptides derived from peptidoglycans, polysaccharides, proteins, and organic acids that are excreted by living bacteria or released after bacterial lysis.
View Article and Find Full Text PDFA comprehensive insights of cancer immunotherapy resistance.
Med Oncol
January 2025
Department of In Vivo Pharmacology, TCG Lifesciences Pvt. Ltd, BN 7, Sector V, Salt Lake City, Kolkata, West Bengal, 700091, India.
Cancer is a major global health issue that is usually treated with multiple therapies, such as chemotherapy and targeted therapies like immunotherapy. Immunotherapy is a new and alternative approach to treating various types of cancer that are difficult to treat with other methods. Although immune checkpoint inhibitors have shown promise for long-term efficacy, they have limited effectiveness in common cancer types such as breast, prostate, and lung.
View Article and Find Full Text PDFIncisional PSMA PET/CT-positive recurrences in prostate cancer- is there an implication on clinical care?
Clin Exp Metastasis
January 2025
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Oligorecurrent prostate cancer (PCa) can be treated with metastasis-directed therapy (MDT), which may be performed using radioguided surgery (RGS) as an experimental approach. These procedures have shown promising outcomes, largely due to the high lesion detection rate of positron emission tomography/computed tomography (PET/CT). We present a case series of patients who underwent RGS following robot-assisted radical prostatectomy (RARP).
View Article and Find Full Text PDFTalazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study.
Future Oncol
January 2025
uHuntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA.
Exploring the Correlation Between Multiparameters Detected in Primary Prostate Cancer using F‑18 PSMA‑1007 PET/MRI and their Potential for Predicting Metastasis.
Nucl Med Mol Imaging
February 2025
National Cyclotron and PET Centre, Chulabhorn Hospital, 906 Kamphaeng Phet 6 Rd., Talat Bang Khen, Lak Si, Bangkok, 10210 Thailand.
Purpose: Prostate-specific membrane antigen (PSMA) Positron emission tomography/magnetic resonance imaging (PET/MRI) surpasses conventional MRI (cMRI) in prostate cancer (PCa) evaluation. Our objective is to evaluate correlation of quantitative parameters in PCa using Fluorine-18 (F-18) PSMA-1007 PET/MRI and their potential for predicting metastases.
Methods: This retrospective study included 51 PCa patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!